Kapitalo Investimentos Ltda Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Kapitalo Investimentos Ltda increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 38.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 6,288 shares of the medical equipment provider’s stock after acquiring an additional 1,735 shares during the quarter. Hologic accounts for 0.3% of Kapitalo Investimentos Ltda’s portfolio, making the stock its 23rd largest position. Kapitalo Investimentos Ltda’s holdings in Hologic were worth $453,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. Benson Investment Management Company Inc. acquired a new position in shares of Hologic during the 4th quarter worth $4,832,000. Principal Financial Group Inc. raised its position in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Clean Yield Group lifted its holdings in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after purchasing an additional 7,266 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after purchasing an additional 238,222 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $58.36 on Wednesday. The business has a 50-day moving average of $60.78 and a two-hundred day moving average of $69.69. The firm has a market capitalization of $13.10 billion, a PE ratio of 18.41, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on HOLX shares. Evercore ISI lowered their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Stephens reiterated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.